PLEASANTON, Calif., July 25 /EMWNews/ -- Thoratec

Corporation (Nasdaq: THOR) a world leader in device-based mechanical

circulatory support therapies to save, support and restore failing hearts,

today announced that it will report its operating results for the second

quarter and first six months of fiscal 2008 on Thursday, July 31.



    The company will hold a conference call to discuss its financial

results and operating activities to all interested parties at 1:30 p.m.,

Pacific Daylight Time (4:30 p.m., Eastern Daylight Time), Thursday, July

31, hosted by Gary F. Burbach, president and chief executive officer, and

David Smith, executive vice president and chief financial officer.



    The teleconference can be accessed by calling (913) 312-0379, passcode

4566478. Please dial in 10-15 minutes prior to the beginning of the call.

The webcast will be available on the Internet at http://phx.corporate-

ir.net/phoenix.zhtml?p=irol-eventDetails&c=95989&eventID=1890100 or at

http://www.thoratec.com



    A replay of the conference call will be available through Thursday,

August 7, via http://www.thoratec.com or by telephone at (719) 457-0820,

passcode 4566478.



    Thoratec Corporation is a world leader in therapies to address

advanced-stage heart failure. The company's product lines include the

Thoratec(R) VAD (Ventricular Assist Device) and HeartMate (R) LVAS (Left

Ventricular Assist System) with nearly 12,000 devices implanted in patients

suffering from heart failure. Additionally, its International Technidyne

Corporation (ITC) division supplies point-of-care blood testing and skin

incision products. Thoratec is headquartered in Pleasanton, California. For

more information, visit the company's web sites at http://www.thoratec.com

or http://www.itcmed.com